ClinicalTrials.gg
Not yet recruitingNCT07951723Updated Nov 20, 2026

Enhanced Expiratory Rebreathing Space Therapy for Complex Sleep Apnea in Patients With Cardiovascular Disease

An interventional study of Enhanced Expiratory Rebreathing Space (EERS) Therapy and Automatic Positive Airway Pressure (APAP) Therapy in Complex Sleep Apnea and Cardiovascular Diseases (CVD), sponsored by Chinese Pulmonary Vascular Disease Research Group. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Chinese Pulmonary Vascular Disease Research Group · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the effectiveness and safety of enhanced expiratory rebreathing space (EERS) therapy compared with conventional automatic positive airway pressure (APAP) therapy in patients with cardiovascular disease and complex sleep apnea (CompSA).

This is a prospective, single-center, randomized controlled trial involving 40 participants aged 18-75 years. Eligible participants will be randomly assigned to either the EERS group or the conventional APAP group in a 1:1 ratio. Participants in the EERS group will receive individualized EERS therapy guided by overnight sleep monitoring, while those in the control group will receive conventional APAP therapy.

Each participant will be followed for five weeks, including a one-week screening period, a two-week treatment period, and a two-week follow-up period. The primary outcome is the apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour of sleep, assessed after two weeks of treatment. Additional outcomes include other sleep-related breathing measures, cardiovascular health indicators, treatment adherence, comfort, and adverse events.

The findings may help determine whether EERS therapy is an effective and safe treatment option for complex sleep apnea in patients with cardiovascular disease.

02

Conditions studied

  • Complex Sleep Apnea
  • Cardiovascular Diseases (CVD)
03

In context

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 674 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18-75 years.
  2. A documented history of at least one cardiovascular disease, including hypertension, coronary artery disease, chronic heart failure, cardiac arrhythmia, pulmonary arterial hypertension, or pulmonary embolism, with clinically stable disease for at least three months.
  3. Complex sleep apnea (CompSA) identified by overnight sleep monitoring, with an apnea-hypopnea index (AHI) ≥15 events/hour and respiratory self-similarity >20%.
  4. Willingness to receive noninvasive positive airway pressure therapy and ability to comply with home-based treatment.
  5. Provision of written .

Exclusion criteria

Exclusion Criteria:

  1. Severe hepatic or renal dysfunction or severe hypotension.
  2. .
  3. Neuromuscular disorders.
  4. Acute aortic dissection.
  5. Acute pericarditis or acute myocarditis.
  6. Acute upper respiratory tract infection or pulmonary infection.
  7. Type II respiratory failure (hypercapnic respiratory failure).
  8. Acute stroke.
  9. Pregnancy or breastfeeding.
  10. Severe facial deformity or a history of maxillofacial surgery that prevents appropriate mask fitting.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Enhanced Expiratory Rebreathing Space (EERS) Therapy

    Device: Enhanced Expiratory Rebreathing Space (EERS) Therapy

  • Active comparator
    Conventional Positive Airway Pressure Therapy

    Device: Automatic Positive Airway Pressure (APAP) Therapy

Interventions

  • DeviceEnhanced Expiratory Rebreathing Space (EERS) Therapy

    Participants will undergo individualized manual continuous positive airway pressure (CPAP) titration under overnight polysomnographic (PSG) monitoring. An enhanced expiratory rebreathing space (EERS) device will be connected between the patient interface and a single-level CPAP device to increase expiratory carbon dioxide rebreathing and stabilize respiratory control. End-tidal carbon dioxide (EtCO₂) will be monitored throughout titration. CPAP pressure will initially be set at 4-6 cmH₂O and manually adjusted by trained sleep technicians in increments of 1-2 cmH₂O to eliminate obstructive respiratory events. The lowest effective pressure will be selected for subsequent treatment. Participants will then receive home-based CPAP therapy combined with EERS for two weeks.

  • DeviceAutomatic Positive Airway Pressure (APAP) Therapy

    Participants will undergo conventional automatic positive airway pressure (APAP) titration during overnight sleep monitoring using a single-level noninvasive positive airway pressure device and a nasal or oronasal mask. The initial pressure range will be set at 4-18 cmH₂O. The device will automatically adjust airway pressure in response to obstructive respiratory events, including apnea, hypopnea, snoring, and airflow limitation. Sleep technicians will monitor respiratory signals, oxygen saturation, mask leakage, and treatment tolerance. Individualized treatment settings will be determined based on overnight titration results, followed by two weeks of home-based positive airway pressure therapy.

06

What researchers measure

Primary outcomes

  1. Apnea-Hypopnea Index (AHI) After Two Weeks of Treatment

    The apnea-hypopnea index (AHI) will be measured during overnight sleep monitoring while participants receive their assigned positive airway pressure therapy after two weeks of treatment. AHI is defined as the total number of apnea and hypopnea events per hour of sleep. Respiratory events will be scored according to the American Academy of Sleep Medicine (AASM) criteria. Lower AHI values indicate fewer sleep-disordered breathing events.

    Time frame: 2 weeks after initiation of treatment

Secondary outcomes

  1. Residual Central Apnea Index (CAI)

    The residual central apnea index (CAI) will be assessed during overnight sleep monitoring while participants receive their assigned treatment. CAI is defined as the number of central apnea events per hour of sleep, with lower values indicating fewer central respiratory events.

    Time frame: 2 weeks after initiation of treatment

  2. Minimum Nocturnal Oxygen Saturation (SpO₂)

    The lowest peripheral oxygen saturation (%) recorded during overnight sleep monitoring while participants receive their assigned treatment.

    Time frame: 2 weeks after initiation of treatment

  3. Oxygen Desaturation Index (ODI)

    The number of oxygen desaturation events per hour of sleep, measured during overnight sleep monitoring after two weeks of treatment.

    Time frame: 2 weeks after initiation of treatment

  4. Time Spent With Oxygen Saturation Below 90% (T90)

    The duration of time during overnight sleep monitoring in which peripheral oxygen saturation is below 90%.

    Time frame: 2 weeks after initiation of treatment

  5. Epworth Sleepiness Scale (ESS) Score

    Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS), which ranges from 0 to 24. Higher scores indicate greater daytime sleepiness.

    Time frame: 2 weeks after initiation of treatment

  6. 24-Hour Ambulatory Blood Pressure

    Mean systolic and diastolic blood pressure measured by 24-hour ambulatory blood pressure monitoring.

    Time frame: 2 weeks after initiation of treatment

  7. 24-Hour Ambulatory Electrocardiographic Parameters

    Cardiovascular parameters assessed using 24-hour ambulatory ECG monitoring.

    Time frame: 2 weeks after initiation of treatment

  8. N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)

    Serum NT-proBNP concentration.

    Time frame: 2 weeks after initiation of treatment

  9. Average Nightly Positive Airway Pressure Usage

    Average duration of device use per night, expressed in hours.

    Time frame: During the 2-week intervention period

  10. Patient-Ventilator Asynchrony

    Occurrence of patient-ventilator asynchrony during treatment.

    Time frame: During the 2-week intervention period

  11. Ventilatory Comfort Visual Analog Scale (VAS) Score

    Patient-reported comfort during positive airway pressure therapy.

    Time frame: 2 weeks after initiation of treatment

  12. Incidence of Adverse Events

    The number and proportion of participants experiencing adverse events will be recorded during the two-week intervention period and the subsequent two-week follow-up period. Adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: From initiation of treatment through 2 weeks after treatment completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wojnowski K, Primera G, Johnson KG. 3-minute central apneas: enhanced expiratory rebreathing space to the rescue. J Clin Sleep Med. 2025 Jun 1;21(6):1133-1137. doi: 10.5664/jcsm.11582. PubMed 40012298 ↗
  • Quinn T, Thomas RJ, Heckman EJ. Enhanced expiratory rebreathing space for high loop gain sleep apnea treatment. Front Sleep. 2023 Sep 29;2:1248371. doi: 10.3389/frsle.2023.1248371. eCollection 2023. PubMed 41426461 ↗
  • Gilmartin G, McGeehan B, Vigneault K, Daly RW, Manento M, Weiss JW, Thomas RJ. Treatment of positive airway pressure treatment-associated respiratory instability with enhanced expiratory rebreathing space (EERS). J Clin Sleep Med. 2010 Dec 15;6(6):529-38. PubMed 21206741 ↗
  • Morgenthaler TI, Kuzniar TJ, Wolfe LF, Willes L, McLain WC 3rd, Goldberg R. The complex sleep apnea resolution study: a prospective randomized controlled trial of continuous positive airway pressure versus adaptive servoventilation therapy. Sleep. 2014 May 1;37(5):927-34. doi: 10.5665/sleep.3662. PubMed 24790271 ↗
  • Morgenthaler TI, Kagramanov V, Hanak V, Decker PA. Complex sleep apnea syndrome: is it a unique clinical syndrome? Sleep. 2006 Sep;29(9):1203-9. doi: 10.1093/sleep/29.9.1203. PubMed 17040008 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 202 non-industry interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 60. This study's planned 11 months is below that.

Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 15, 2027
CompletionEst.
Nov 30, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951723
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Qing Zhao, MD, PHD
Contact
zhaoqingfw@aliyun.com
+86 17601015265

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion